JOP20140344B1 - تركيبات وطرق لتقليل المضاعفات السلبية العظمي للقلب والاوعية الدموية - Google Patents
تركيبات وطرق لتقليل المضاعفات السلبية العظمي للقلب والاوعية الدمويةInfo
- Publication number
- JOP20140344B1 JOP20140344B1 JOP/2014/0344A JOP20140344A JOP20140344B1 JO P20140344 B1 JOP20140344 B1 JO P20140344B1 JO P20140344 A JOP20140344 A JO P20140344A JO P20140344 B1 JOP20140344 B1 JO P20140344B1
- Authority
- JO
- Jordan
- Prior art keywords
- adverse cardiovascular
- compositions
- methods
- mace
- cardiovascular events
- Prior art date
Links
- 230000002411 adverse Effects 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000007211 cardiovascular event Effects 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 3
- 206010033307 Overweight Diseases 0.000 abstract 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 abstract 2
- 229960001058 bupropion Drugs 0.000 abstract 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 2
- 229960003086 naltrexone Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يتعلق الطلب الحالي بتركيبات , ادوات , استخدامات , انظمة وطرق لتقليل خطر المضاعفات السلبية العظمي للقلب والاوعية الدموية MACE تضم النالتريكسون والبوبروبيون او الاملاح منها المقبولة صيدليا لتقليل خطر مضاعفات او نتائج القلب والاوعية الدموية العظمي السلبية MACE في الافراد , يفضل هؤلاء عند خطر متزايد من نتائج القلب والاوعية الدموية او مضاعفات القلب والاوعية الدموية العظمي السلبية MACE ويمكن ان يكون لديهم وزن زائد او سمنة , يتعلق الطلب الحالي بتركيبات , ادوات , استخدامات , انظمة وطرق باستخدام النالتريكسون او البوبروبيون او الاملاح منها المقبولة صيدليا لعلاج الوزن الزائد او السمنة في الافراد يفضل في عند خطر متزايد لنتائج او مضاعفات القلب والاوعية الدموية السلبية العظمي , حيث ان العلاج يقلل علاج ال المضاعفات السلبية العظمي للقلب والاوعية الدمويةMACE .
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361913216P | 2013-12-06 | 2013-12-06 | |
US201361914938P | 2013-12-11 | 2013-12-11 | |
US201461984580P | 2014-04-25 | 2014-04-25 | |
US14/322,810 US8969371B1 (en) | 2013-12-06 | 2014-07-02 | Compositions and methods for weight loss in at risk patient populations |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20140344B1 true JOP20140344B1 (ar) | 2021-08-17 |
Family
ID=52575014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2014/0344A JOP20140344B1 (ar) | 2013-12-06 | 2014-12-03 | تركيبات وطرق لتقليل المضاعفات السلبية العظمي للقلب والاوعية الدموية |
Country Status (33)
Country | Link |
---|---|
US (8) | US8969371B1 (ar) |
EP (2) | EP3076971B1 (ar) |
JP (2) | JP6665094B2 (ar) |
KR (3) | KR20220165791A (ar) |
CN (3) | CN105899210A (ar) |
AU (1) | AU2014360492A1 (ar) |
BR (1) | BR112016012755A2 (ar) |
CA (1) | CA2932127C (ar) |
CL (1) | CL2016001362A1 (ar) |
CR (1) | CR20160313A (ar) |
CY (1) | CY1125114T1 (ar) |
DK (1) | DK3076971T3 (ar) |
EA (1) | EA201690964A1 (ar) |
EC (1) | ECSP16057765A (ar) |
ES (1) | ES2903391T3 (ar) |
HR (1) | HRP20220058T1 (ar) |
HU (1) | HUE057551T2 (ar) |
IL (3) | IL300870A (ar) |
JO (1) | JOP20140344B1 (ar) |
LT (1) | LT3076971T (ar) |
MX (2) | MX2016007231A (ar) |
PE (1) | PE20161034A1 (ar) |
PL (1) | PL3076971T3 (ar) |
PT (1) | PT3076971T (ar) |
RS (1) | RS62846B1 (ar) |
RU (1) | RU2711638C2 (ar) |
SG (1) | SG10201808055QA (ar) |
SI (1) | SI3076971T1 (ar) |
TN (1) | TN2016000231A1 (ar) |
TW (1) | TWI661826B (ar) |
UY (1) | UY35864A (ar) |
WO (1) | WO2015085044A1 (ar) |
ZA (1) | ZA201603831B (ar) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004096201A1 (en) | 2003-04-29 | 2004-11-11 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
EP2135603B1 (en) | 2005-11-22 | 2013-01-02 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
US8916195B2 (en) * | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
KR20180066272A (ko) | 2006-11-09 | 2018-06-18 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
RU2616496C2 (ru) | 2010-01-11 | 2017-04-17 | Ориксиджен Терапьютикс, Инк. | Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты) |
WO2013184837A1 (en) * | 2012-06-06 | 2013-12-12 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
WO2018027815A1 (zh) * | 2016-08-11 | 2018-02-15 | 华为技术有限公司 | 基于非授权频谱的无线通信方法、基站和终端设备 |
WO2023107640A1 (en) * | 2021-12-09 | 2023-06-15 | Incarda Therapeutics, Inc. | Inhaled therapy for cardiac arrhythmia |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217353A (en) | 1978-05-19 | 1980-08-12 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia |
IL58649A (en) | 1978-11-10 | 1982-04-30 | Beecham Group Ltd | Pharmaceutical dispensing container |
WO1983003197A1 (en) | 1982-03-16 | 1983-09-29 | Univ Rockefeller | Method for controlling gastrointestinal dysmotility |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
ES2058272T3 (es) | 1987-05-04 | 1994-11-01 | Lilly Co Eli | Fluoxetina util para el tratamiento de la diabetes. |
US5403595A (en) | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
DE4136215A1 (de) | 1991-11-02 | 1993-05-06 | Ferring Arzneimittel Gmbh, 2300 Kiel, De | Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie |
US5512593A (en) | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
EP0782445B1 (en) | 1994-09-19 | 2002-03-13 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US5627187A (en) | 1995-04-12 | 1997-05-06 | Katz; Bruce E. | 5-FU for treating actinic kerotoses |
GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
US5716976A (en) | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
WO1997033581A1 (en) | 1996-03-13 | 1997-09-18 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
EP0795327A1 (en) | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
DE69736928T2 (de) | 1996-05-07 | 2007-06-28 | Pliva Istrazivanje I Razvoj D.O.O. | Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus |
CA2258893C (en) | 1996-06-28 | 2005-06-14 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
US5878750A (en) | 1996-11-14 | 1999-03-09 | Clemens; Anton H. | Method of treating the syndrome of coronary heart disease risk factors in humans |
JP2001518520A (ja) | 1997-10-03 | 2001-10-16 | キャリー メディカル コーポレイション | ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物 |
US6262049B1 (en) | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
WO1999038504A1 (en) | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
US6048322A (en) | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
US6210716B1 (en) | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
US6589553B2 (en) | 2001-02-08 | 2003-07-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral dosage form |
NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
EP1215963A4 (en) | 1999-09-15 | 2005-07-27 | Elan Pharm Inc | METHOD FOR THE TREATMENT OF NEUROPATHIC PAIN USING HETEROARYLMETHANSULFONAMIDES |
US6403657B1 (en) | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
GB0001449D0 (en) | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
US20020055512A1 (en) | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
CA2397726A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
BR0108379A (pt) | 2000-02-08 | 2002-11-05 | Euro Celtique Sa | Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide |
US6306436B1 (en) | 2000-04-28 | 2001-10-23 | Teva Pharmaceuticals Usa, Inc. | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride |
US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
JP5161412B2 (ja) | 2000-09-18 | 2013-03-13 | サノス・バイオサイエンス・アクティーゼルスカブ | Glp−1及びglp−2ペプチドの使用方法 |
AU2002314968B2 (en) | 2001-06-08 | 2006-12-07 | Endo Pharmaceuticals, Inc. | Controlled release dosage forms using acrylic polymer, and process for making the same |
KR20040060917A (ko) | 2001-08-06 | 2004-07-06 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 남용을 방지하기 위한 조성물 및 방법 |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
HUP0401191A3 (en) | 2001-08-06 | 2006-11-28 | Euro Celtique Sa | Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US20040102440A1 (en) | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
US20040029941A1 (en) | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
AU2003231788B2 (en) | 2002-05-17 | 2008-09-11 | Duke University | Method for treating obesity |
KR101108014B1 (ko) | 2002-05-17 | 2012-01-25 | 티오가 파마슈티칼스, 인코포레이티드 | 선택성 아편제 수용체 조절인자로서 효과적인 화합물의 용도 |
US20040005368A1 (en) | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
US6972291B2 (en) | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
US7086532B2 (en) | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
WO2004024096A2 (en) | 2002-09-13 | 2004-03-25 | Eisai Co., Ltd. | Method of treating tremors |
US20040192715A1 (en) | 2003-02-05 | 2004-09-30 | Mark Chasin | Methods of administering opioid antagonists and compositions thereof |
US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
EP1613324A2 (en) | 2003-04-14 | 2006-01-11 | Pain Therapeutics, Inc. | Methods for the treatment of pain comprising opioid antagonists |
WO2004096201A1 (en) | 2003-04-29 | 2004-11-11 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
JP2006528676A (ja) | 2003-05-16 | 2006-12-21 | ファイザー・プロダクツ・インク | 非定形型抗精神病薬と、gaba調節薬及び/又は抗痙攣薬の治療上の組合せ |
WO2004110375A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
JP4758897B2 (ja) | 2003-09-25 | 2011-08-31 | ユーロ−セルティーク エス.エイ. | ヒドロコドンとナルトレキソンとの併用医薬 |
US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
US20070149451A1 (en) | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
KR20060128995A (ko) | 2004-01-13 | 2006-12-14 | 듀크 유니버시티 | 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물 |
US20050245541A1 (en) | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
US20050277579A1 (en) | 2004-05-03 | 2005-12-15 | Ranga Krishnan | Compositions for affecting weight loss |
US20050250838A1 (en) | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
AU2005271574A1 (en) | 2004-08-03 | 2006-02-16 | Orexigen Therapeutics, Inc. | Combination of bupropion and a second compound for affecting weight loss |
WO2007047351A2 (en) | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
US20070099947A1 (en) | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
EP2135603B1 (en) | 2005-11-22 | 2013-01-02 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
WO2007089318A2 (en) | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
EP1954316A1 (en) | 2005-11-28 | 2008-08-13 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
WO2007145863A2 (en) | 2006-06-05 | 2007-12-21 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
DK2526932T3 (en) | 2006-06-19 | 2017-07-17 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
CA2693992C (en) | 2006-07-20 | 2017-01-31 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
US8682445B2 (en) | 2006-07-28 | 2014-03-25 | Cyberonics, Inc. | Patient management system for treating depression using an implantable medical device |
TWI609702B (zh) * | 2006-11-09 | 2018-01-01 | 歐瑞根治療有限公司 | 層狀醫藥調配物 |
KR20180066272A (ko) | 2006-11-09 | 2018-06-18 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
GB2447949B (en) | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
RU2616496C2 (ru) | 2010-01-11 | 2017-04-17 | Ориксиджен Терапьютикс, Инк. | Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты) |
EP2646011B1 (en) | 2010-12-03 | 2017-08-16 | Orexigen Therapeutics, Inc. | Methods for reducing binge or compulsive eating |
WO2013184837A1 (en) * | 2012-06-06 | 2013-12-12 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
-
2014
- 2014-07-02 US US14/322,810 patent/US8969371B1/en active Active
- 2014-12-03 JO JOP/2014/0344A patent/JOP20140344B1/ar active
- 2014-12-04 CR CR20160313A patent/CR20160313A/es unknown
- 2014-12-04 PT PT148671910T patent/PT3076971T/pt unknown
- 2014-12-04 ES ES14867191T patent/ES2903391T3/es active Active
- 2014-12-04 EA EA201690964A patent/EA201690964A1/ru unknown
- 2014-12-04 PE PE2016000724A patent/PE20161034A1/es unknown
- 2014-12-04 EP EP14867191.0A patent/EP3076971B1/en active Active
- 2014-12-04 CN CN201480072729.8A patent/CN105899210A/zh active Pending
- 2014-12-04 KR KR1020227041333A patent/KR20220165791A/ko not_active Application Discontinuation
- 2014-12-04 US US15/101,878 patent/US10231962B2/en active Active
- 2014-12-04 RU RU2016122483A patent/RU2711638C2/ru active
- 2014-12-04 HU HUE14867191A patent/HUE057551T2/hu unknown
- 2014-12-04 KR KR1020237036479A patent/KR20230152800A/ko not_active Application Discontinuation
- 2014-12-04 UY UY0001035864A patent/UY35864A/es not_active Application Discontinuation
- 2014-12-04 HR HRP20220058TT patent/HRP20220058T1/hr unknown
- 2014-12-04 CN CN202310405573.1A patent/CN117159547A/zh active Pending
- 2014-12-04 WO PCT/US2014/068527 patent/WO2015085044A1/en active Application Filing
- 2014-12-04 RS RS20220039A patent/RS62846B1/sr unknown
- 2014-12-04 LT LTEPPCT/US2014/068527T patent/LT3076971T/lt unknown
- 2014-12-04 SG SG10201808055QA patent/SG10201808055QA/en unknown
- 2014-12-04 DK DK14867191.0T patent/DK3076971T3/da active
- 2014-12-04 BR BR112016012755A patent/BR112016012755A2/pt not_active Application Discontinuation
- 2014-12-04 TN TN2016000231A patent/TN2016000231A1/en unknown
- 2014-12-04 EP EP21202875.7A patent/EP4005571A1/en active Pending
- 2014-12-04 IL IL300870A patent/IL300870A/en unknown
- 2014-12-04 SI SI201431935T patent/SI3076971T1/sl unknown
- 2014-12-04 CN CN202111066895.5A patent/CN114404419A/zh active Pending
- 2014-12-04 JP JP2016536659A patent/JP6665094B2/ja active Active
- 2014-12-04 AU AU2014360492A patent/AU2014360492A1/en not_active Abandoned
- 2014-12-04 CA CA2932127A patent/CA2932127C/en active Active
- 2014-12-04 KR KR1020167017977A patent/KR102472432B1/ko active IP Right Grant
- 2014-12-04 PL PL14867191T patent/PL3076971T3/pl unknown
- 2014-12-04 MX MX2016007231A patent/MX2016007231A/es unknown
- 2014-12-05 TW TW103142498A patent/TWI661826B/zh active
-
2015
- 2015-03-02 US US14/635,518 patent/US9119850B2/en active Active
- 2015-08-28 US US14/839,792 patent/US9801875B2/en active Active
-
2016
- 2016-05-30 IL IL245919A patent/IL245919A0/en unknown
- 2016-06-02 MX MX2022001251A patent/MX2022001251A/es unknown
- 2016-06-03 CL CL2016001362A patent/CL2016001362A1/es unknown
- 2016-06-06 ZA ZA2016/03831A patent/ZA201603831B/en unknown
- 2016-07-04 EC ECIEPI201657765A patent/ECSP16057765A/es unknown
-
2017
- 2017-10-05 US US15/725,830 patent/US10231964B2/en active Active
-
2019
- 2019-03-18 US US16/356,657 patent/US10828294B2/en active Active
- 2019-03-18 US US16/356,663 patent/US10835527B2/en active Active
- 2019-12-05 JP JP2019220444A patent/JP7204634B2/ja active Active
-
2020
- 2020-11-16 US US17/099,316 patent/US11998542B2/en active Active
-
2021
- 2021-04-07 IL IL282117A patent/IL282117A/en unknown
-
2022
- 2022-01-19 CY CY20221100048T patent/CY1125114T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001251A (es) | Composiciones y metodos para reducir eventos adversos cardiovasculares graves. | |
MX2021002406A (es) | Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica. | |
PH12015502310B1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
MX2015009105A (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
CY1123183T1 (el) | Συνθεση για χρηση σε μια μεθοδο θεραπειας υπερβολικου βαρους και παχυσαρκιας σε ασθενεις με υψηλο καρδιαγγειακο κινδυνο | |
PH12016501122A1 (en) | Delayed release compositions of linaclotide | |
MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
MX359639B (es) | Metodos y composiciones para uso en tratamientos celulares. | |
MX2016004741A (es) | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. | |
UA115357C2 (uk) | Похідні піридин-4-ілу | |
MY161601A (en) | Films and compositions comprising the same | |
EP2971030B8 (en) | Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes | |
WO2014152420A3 (en) | Product and method for treating diarrhea | |
MX2017009929A (es) | Composiciones y métodos para metabolismo muscular mejorado. | |
WO2014146111A3 (en) | Analgesic compounds and methods of use | |
PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
MX2015002934A (es) | Metodos de administracion de rifaximina para perdida de peso y tratamiento de obesidad. | |
GB2527233A (en) | Composition comprising hydrocortisone | |
WO2015013285A3 (en) | Methods for reducing the occurrence of hot flashes | |
IN2013MU02055A (ar) | ||
MX2012010006A (es) | Agonistas de a3ar para el tratamiento de uveitis. | |
IN2013MU01983A (ar) |